What we're reading, December 13, 2016: 1 in 6 American adults are prescribed psychiatric drugs; veterans groups want Donald Trump to keep the current Veterans Affairs secretary; and the number of drug-affected newborns is rising more in rural areas.
One in 6 American adults were prescribed a psychiatric drug in the past year, and the number is higher for white Americans. According to TIME, white Americans are twice as likely as other racial groups to report taking antidepressants, antipsychotics, and similar drugs. Only 9% of Hispanics, 10% of blacks, and 5% of Asians were prescribed psychiatric drugs, compared with more than 20% of white Americans. Antidepressants were the most common psychiatric prescription filled in the last year, and the majority (80%) were taking psychiatric drugs for long-term use.
As President-elect Donald J. Trump meets with an ever-growing number of people to fill various positions in his administration, there is one person he is being asked to keep. Groups that represent veterans want Trump to keep the current secretary of Veterans Affairs, picked by President Barack Obama, reported The New York Times. The groups prefer Robert A. McDonald because they are concerned about the inexperience of Trump’s rumored candidates and how they would impact the veterans healthcare system. A total of 5 groups representing hundreds of thousands of veterans have thrown their weight behind McDonald.
Driven by the rising use of opioids, the number of drug-affected infants being born has increased sharply, and AP reported that rural areas are being affected more. In 2004, the problem was about the same in rural and urban areas, but the rural rate has climbed to 8 births affected for every 1000 births compared with just 5 in 1000 births in urban areas. These newborns are at risk for withdrawal symptoms, such as problems with breathing, sleeping, and feeding, and may need to be hospitalized for weeks or months to be treated.
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Study Highlights BMP7 as a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More